HPV vaccination provides protection for immunocompromised children
A quadrivalent human papillomavirus vaccine provided adequate seroconversion response rates in immunocompromised children, according to Dr. C. Raina MacIntyre, MBBS, PhD, and her associates.
In a clinical trial of 59 immunocompromised children aged 5-18, seroconversion rates for HPV types 6, 11,...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Cervical Cancer Vaccine | Children | Clinical Trials | Dermatology | Gardasil | Genital Warts | Human Papillomavirus (HPV) | Skin | Vaccines